Clinical research teams are under pressure to move faster, stay compliant, and do more with limited resources. For small and scaling teams, that pressure is often worsened by disconnected vendors, separate systems, and manual handoffs.
Medrio’s 2026 roadmap is focused on removing difficulties. We are investing in faster performance, a more connected product experience, and solutions for the full clinical trial lifecycle.
These changes reflect what customers have told us they need most. They also reflect the biggest shift in our product direction in 20 years.
In this article, you’ll find:
- What progress has been made
- What to expect in remaining 2026 releases
- How Medrio’s “one partner” vision is taking shape
- Why customers should consider the Early Adopter Program
- What current customers can expect during this transition
What Medrio has delivered for clients so far
In 2026, we’ve made more updates to existing products than in the last two years combined. They are designed to support customers now, while we continue building more Medrio solutions.
Updates included bug fixes, critical improvements, and performance enhancements across the platform, including:
- Refreshed user interface in EDC, ePRO, and eConsent.
- Improved configuration of and expanded formatting options for NRS (numerical rating scale) and VAS (visual analogue scale) assessments.
- Increased flexibility for re-consent workflows in eConsent.
- Enhanced integrations, both within and outside the Medrio ecosystem.
Expanding the Medrio ecosystem
Sponsors and CROs need a more connected way to manage clinical trials. That’s why Medrio continues to expand beyond its core EDC foundation into a broader eClinical suite.
Medrio CTMS is already seeing live customer usage. Meanwhile, Medrio eTMF is underway with customer feedback shaping the workflows, requirements, and use cases behind the product.
What to know about upcoming 2026 Medrio product releases
Throughout the second half of the year, Medrio will deliver its final two releases for 2026 that include ongoing platform enhancements, key system connectors, and reporting improvements.
Other updates include:
- MCP connectors: A planned August launch that will make it easier for users to find the data they need quickly. It will simplify data exploration and support more intuitive and scalable analysis, right in the AI tools customers are already using.
- Further reporting improvements: Backend reporting updates, with early results showing a 90% reduction in data refresh times.
- Ongoing product updates: Bug fixes, critical updates, and customer-driven improvements.
Why our “One Partner” vision is a priority
In our most significant technological shift since 2005, Medrio is moving to a completely modernized architecture. By doing so, we’re tackling the fragmentation sponsors and CROs face with multiple vendors, contracts, and logins.
Customers will benefit from the simplicity of one contract, one login, and one cohesive partner experience across the full clinical trial lifecycle.
This vision is not a distant concept. Our team has been building this architecture behind the scenes, and customers are already adopting new releases.
The work is focused on three priorities:
- Suite expansion: You get a more comprehensive and connected solution suite to support your trials.
- AI enhancement: Benefit from AI features designed to improve efficiency, while we build new products faster with AI-assisted development.
- Platform modernization: Access modernized core platform components to improve speed, scalability, and long-term performance.
Why join Medrio’s Early Adopter Program
Customer feedback is important to us. That’s why we’re running an early adopter program where customers collaborate with us to help develop our new solutions.
Through the Early Adopter Program, customers can work directly with our product team. This connection gives sponsors and CROs a chance to influence development before general release.
Early adopters can share how their teams manage study startup, monitoring, documentation, reporting, and cross-functional oversight. That feedback ensures Medrio supports your real workflows, not assumptions.
Are you a Medrio customer who wants to join the Early Adopter program or learn more about Medrio’s roadmap? Contact your Medrio rep today.
Our commitment to you
Any roadmap shift can raise questions for customers or organizations considering working with Medrio. You may want to better understand what is changing and whether active studies will be disrupted.
Current Medrio solutions will be supported, maintained, and improved. Active studies will continue to run seamlessly for years. Customers should not expect a sudden break from the solutions and workflows they rely on today.
Medrio’s commitment to customers:
- Total continuity
- Continuous improvement
- Performance gains
We are being intentional about release timing. Major releases are planned for July and September, which helps customers avoid validation strain during Q4.
This roadmap is an upgrade—not a replacement of our customer commitments. We are building new solutions while continuing to strengthen the platform customers already trust.
Want to learn more about how Medrio can support your next study? Book a demo.
